Pharmaceuticals APAC News & Press Release Distribution

Pharmaceuticals

All
Global

EuroPCR 2023 | 6 Month Outcome of the SMART Study: satisfactory BP control achieved with reduced medication burden

PARIS, May 19, 2023 /PRNewswire/ -- On May 17th 2023, the six-month result of the SMART Study (Sympathetic Mapping/Ablation Renal nerves for Treatment of hypertension Trial; NCT02761811) was released on the Late Breaking Clinical Trial conference, reporting ground-breaking findings in the field o...

2023-05-19 14:54 1680

The First of Its Kind in the World: The Recombinant Multivalent COVID-19 Protein Vaccine against XBB Variants by WestVac Biopharma/West China Medical Center, Sichuan University has been Approved for Clinical Trials by The National Medical Products Administration of China.

CHENGDU, China, May 18, 2023 /PRNewswire/ -- On May 17, 2023, Recombinant bivalent COVID-19 protein vaccine (Sf9 cells) and recombinant trivalent COVID-19 trimeric protein vaccine (Sf9 cells) developed by WestVac Biopharma/ West China Medical Center,Sichuan University against the most recent cir...

2023-05-18 21:23 4093

The First of Its Kind in the World: The Recombinant Multivalent COVID-19 Protein Vaccine against XBB Variants by WestVac Biopharma/West China Medical Center, Sichuan University has been Approved for Clinical Trials by The National Medical Products Administration of China.

YS Biopharma to Participate in the Virtual Benchmark Healthcare House Call Conference on May 23, 2023

GAITHERSBURG, Md., May 18, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseas...

2023-05-18 20:25 3766

Kapruvia® (difelikefalin) recommended by England's NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus

Recommendation will enable eligible patients in England, Wales and Northern Ireland to access the first licensed treatment for moderate-to-severe chronic kidney disease (CKD)-associated pruritus in adult patients on haemodialysis ST. GALLEN, Switzerland and STAMFORD, Conn., May 18, 2023 /PRNewswi...

2023-05-18 14:00 3321

Antengene Announces Clearance of U.S. IND for the Phase I Trial of First-in-Class Anti-CD24 Monoclonal Antibody ATG-031

* ATG-031, discovered and developed in-house by Antengene, is the world's first anti-CD24 antibody to advance to the clinic in oncologyand Antengene's third drug candidate to enter clinical studies in the U.S. * The Phase I "PERFORM" study will evaluate the safety and tolerability, pharmacolo...

2023-05-18 11:53 2881

Providence-based "Biotech start up" EpiVax Celebrates 25th Anniversary

PROVIDENCE, R.I., May 17, 2023 /PRNewswire/ -- EpiVax, Inc. ("EpiVax") is celebrating its 25th birthday by renewing the company's commitment to improving human health everywhere while highlighting the development of groundbreaking tools by the company. In addition, EpiVax is celebrating the work ...

2023-05-17 23:49 2313

Insilico Medicine Successfully Explores the Advantages of Quantum Generative Adversarial Networks in Generative Chemistry

NEW YORK, May 17, 2023 /PRNewswire/ -- Insilico Medicine, a clinical stage generative artificial intelligence (AI)-driven drug discovery company, today announced that it groundbreakingly combines two rapidly developing technologies, quantum computing and generative AI to explore the lead candidat...

2023-05-17 18:00 2859

Inclusion of Recbio In the MSCI China Small Cap Index

TAIZHOU, China, May 17, 2023 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the "Company", together with its subsidiaries, the "Group") is pleased to announce that, MSCI announced the results of the semi-annual review of the MSCI Global Small Cap Indexes onMay 12, 2023, and the Company has ...

2023-05-17 14:01 5494

Antengene Announces NDA Submission for XPOVIO® in Indonesia

SHANGHAI and HONG KONG, May 17, 2023 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hema...

2023-05-17 08:30 2623

Transcenta Announces Encouraging Phase I Clinical Data of TST002 (Blosozumab) in Chinese Patients with Reduced Bone Mineral Density

SUZHOU, China, May 17, 2023 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics,announces encouraging phase I cl...

2023-05-17 08:17 2172

Innovent Announces Clinical Data of Multiple Trials Will be Presented at the 2023 ASCO and EHA Annual Meetings

ROCKVILLE, Md. and SUZHOU, China, May 17, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and...

2023-05-17 08:00 4125

Everest Medicines Announces Completion of Patient Enrollment in Phase 3 Clinical Trial of Etrasimod in Asia

SHANGHAI, May 17, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, announced today the completion of patient enrollment in a multi-...

2023-05-17 07:48 3649

DEBIOPHARM LAUNCHES PHASE 1/2 COMBINATION TRIAL INVESTIGATING BRAIN-PENETRANT SELECTIVE WEE1 INHIBITOR FOR BRAIN CANCER PATIENTS

* Glioblastomas (GBM) are among the most aggressive and lethal tumors of the central nervous system with a 5-year survival rate of only 6.8%. * Debiopharm is combining its potent, brain penetrant WEE1 inhibitor Debio 0123 with standard of care (SOC) therapy. Debio 0123 hopes to hinder DNA dama...

2023-05-17 07:00 2055

Boan Biotech's BA1202 Approved for Clinical Trial

-The First Novel CEA/CD3 Bispecific Antibody in China- YANTAI, China, May 16, 2023 /PRNewswire/ -- Boan Biotech announced today that its BA1202, a CEACAM5 (CEA)/CD3 bispecific antibody, has been approved for a clinical trial by the Center for Drug Evaluation ofChina's National Medical Products A...

2023-05-16 22:02 5285

DxVx appoints Yong Gu Lee as new CEO and Kevin Kwon as the new president

- Reorganizing the global sales networks and enhancing its capabilities to get global approvals for new drug - Accelerating value of the new drug pipelines SEOUL, South Korea, May 16, 2023 /PRNewswire/ -- DxVx announced on the 16th, the board of directors appointedYong Gu Lee as the new CEO and ...

2023-05-16 21:00 2480

DxVx appoints Yong Gu Lee as new CEO and Kevin Kwon as the new president

YS Biopharma's PIKA Rabies Vaccine Receives Phase 3 Clinical Trial Approval in Pakistan

GAITHERSBURG, Md., May 16, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and commercializing new generations of vaccines and therapeutic biologics for infectious d...

2023-05-16 19:00 1970

Cambrex Completes Expansion of Snapdragon Chemistry Facility in Waltham, Massachusetts

EAST RUTHERFORD, N.J., May 16, 2023 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO) providing drug substance, drug product, and analytical services across the entire drug lifecycle, today announced that Snapdragon Chemistry has completed the se...

2023-05-16 18:00 2205

LYNK's LNK01001 Achieved Exciting Phase II Results in Rheumatoid Arthritis

HANGZHOU, China, May 16, 2023 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as 'Lynk Pharmaceuticals'), an innovative clinical stage company, announced that the Phase II clinical trial of LNK01001 in the treatment of rheumatoid arthritis (RA) showed statistically signifi...

2023-05-16 08:00 3741

Patient Enrollment Completed for Phase III Clinical Trial of Boan Biotech's Dulaglutide Injection BA5101 in China

YANTAI, China, May 15, 2023 /PRNewswire/ -- Boan Biotech today announced the completion of patient enrollment for the Phase III clinical trial (a comparative clinical study of efficacy and safety) of the company's Dulaglutide Injection (BA5101) inChina. BA5101 is a biosimilar of Trulicity®, used...

2023-05-15 21:58 3846

Hummingbird Bioscience and Merck Enter Collaboration to Evaluate HMBD-001 In Squamous Non-Small Cell Lung Carcinoma

* Hummingbird Bioscience enters a clinical trial collaboration and supply agreement with Merck to evaluate HMBD-001, a potentially best-in-class anti-HER3 mAb, in combination with cetuximab, an anti-EGFR mAb, in sqNSCLC * HMBD-001 used as monotherapy and in combination with cetuximab has been ...

2023-05-15 18:30 2175

1 ... 32 33 343536 37 38 ... 181